Akriveia Therapeutics
Skillman, US · Founded 2016 · Delaware LLC · 1 known investors
Founders & leadership
ST
Simon TomlinsonExecutive
Board
TB
Thomas BeckBoard director
BA
Benjamin AuspitzBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.5M disclosed across 2 rounds · 2016–2018
▶$3MraisedJan 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin AuspitzDirector
- Thomas BeckDirector
- Michael GladstoneDirector
- Simon TomlinsonExecutive Officer, Director
- David GrayzelDirector
- Offering amount
- $22.5M
- Amount sold
- $3M
- First sale
- Jan 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$4.5MraisedJun 2016 · 1 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJun 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas BeckDirector
- Benjamin AuspitzDirector
- Simon TomlinsonExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $4.5M
- Finders' fees
- $45K
- Placement agents
- Walter Greenblatt
- First sale
- May 2016
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Akriveia Therapeutics's investors?
- Akriveia Therapeutics's investors include Atlas Venture.
- How much funding has Akriveia Therapeutics raised?
- Akriveia Therapeutics has disclosed $7.5M raised across 2 rounds.
- Where is Akriveia Therapeutics headquartered?
- Akriveia Therapeutics is headquartered in Skillman, US.